Physician profile
Sidharth Puri
NPI 1609116474
$32,195.94
in general payments reported to CMS, 2019-2025
22 companies · $16K in 2025
The $16K reported for 2025 was more than what 93% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,094 · 2020: $985 · 2021: $1,862 · 2022: $7,077 · 2023: $1,798 · 2024: $2,026 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $15K · Food and Beverage: $3,020 · Travel and Lodging: $1,768 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $14,890.00 |
| Food and Beverage | $3,020.16 |
| Travel and Lodging | $1,768.44 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $16,108.90 | 2025 | Purified Cortrophin Gel, Yutiq, Iluvien |
| Alimera Sciences, INC. | $11,459.51 | 2020-2024 | Iluvien, Yutiq |
| Alcon Vision LLC | $1,565.73 | 2019 | |
| Lupin INC. | $500.00 | 2023 | |
| Apellis Pharmaceuticals, INC. | $462.61 | 2022-2025 | Syfovre |
| Allergan, INC. | $345.62 | 2019-2020 | |
| Eyepoint US, INC. | $197.60 | 2022-2023 | |
| Astellas Pharma US INC | $192.31 | 2023-2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $174.09 | 2019 | |
| Glaukos Corporation | $162.03 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $150.86 | 2020-2023 | Eylea |
| Coherus Oncology, INC. | $139.04 | 2023 | |
| Mallinckrodt Hospital Products INC. | $124.99 | 2023 | Acthar |
| Kala Pharmaceuticals, INC. | $119.70 | 2019 | |
| Astellas Pharma Global Development | $112.82 | 2024 | Izervay |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dutch Ophthalmic, USA | $104.85 | 2023 | Tissueblue, Eva, Combined Machine |
| Abbvie INC. | $100.00 | 2022 | |
| Harrow Eye, LLC | $90.54 | 2024-2025 | Iheezo |
| Bausch & Lomb Americas INC. | $57.89 | 2023-2024 | Infuse |
| Dompe US, INC. | $26.85 | 2023 | Oxervate |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidharth Puri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.